Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Development of gene expression signatures for lenalidomide treatement on megakaryocyte

ABSTRACT: Development of gene expression signatures for lenalidomide treatement on megakaryocyte

PROVIDER: PRJNA438898 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Development of gene expression signatures for lenalidomide treatement on megakaryocyte

Project description:To clarify the machinery how lenalidomide inhibit proplatelet formation of megakaryocytes, we performed transcriptome analysis of megakaryocytes derived from human hematopoietic stem/progenitor cells in the liquid culture system with or without lenalidomide. Differentially expressed genes were comprehensively evaluated by gene set enrichment analysis. Untreated megakaryocytes showed the estradiol-responded gene expression signatures, whereas the lenalidomide-treated megakaryocytes did not. Furthermore, we performed a rescue strategy with exogenous estradiol, confirming that lenalidomide-induced inhibition of proplatelet formation should be due to the deficiency of endogenous estradiol action in megakaryocytes.

2018-06-30 | GSE111994 | GEO

Difference in gene expression signatures for progenies of lenalidomide-treated megakaryocyte/erythrocyte progenitors

Project description:To clarigy the molecular mechanism underlying the IMiD-induced megakaryocytic lineage commitment in human megakaryocyte/erythrocyte progenitors, we performed transcriptome analysis of CD41-CD105+ and CD41+CD105- cells obtained from megakaryocyte/erythrocyte progenitors treated with lenalidomide for 72 hours. Differentially expressed genes were comprehensively evaluated by gene set enrichment analysis. CD105-CD41+ cells showed the enrichment in the expression of genes related to megakaryocytes and platelet, whereas genes related to erythroid lineage were negatively enriched. CD41+CD105- cells expressed higher levels of transcription factors required for megakaryocyte differentiation including FLI1, RUNX1, and MEIS1. Furthermore, we performed a knockdown strategy with small interfering RNA against MEIS1 mRNA, confirming that lenalidomide-induced megakaryocyte commitment should be due to the up-regulation of MEIS1 in megakaryocyte/erythrocyte progenitors.

2021-11-25 | GSE162212 | GEO

Difference in gene expression signatures for progenies of lenalidomide-treated megakaryocyte/erythrocyte progenitors

Project description:Difference in gene expression signatures for progenies of lenalidomide-treated megakaryocyte/erythrocyte progenitors

| PRJNA681011 | ENA

Decoding Human Megakaryocyte Development

Project description:Decoding Human Megakaryocyte Development

| PRJNA602526 | ENA

Development of gene signatures of human unipotent megakaryocyte progenitor and other hematopoietic stem and progenitor populations

Project description:We newly identified prospectively-isolatable unipotent megakaryocyte progenitor population (MegP) as the major source of megakaryocytes, which emerges directly from early stage of hematopoiesis bypassing megakaryocyte-erythroid lineage bifurcation and contributes to physiological and pathological human megakaryopoiesis. To explore gene expression signature of hematopoietic stem/progenitor populrations miroarry-based whole transcriptome analysis was performed. As a result, gene expression signature of MegP clearly reflected its differentiation potential.

2016-02-02 | GSE77439 | GEO

Development of gene expression signatures for NSCLC

Project description:Development of gene expression signatures for NSCLC

| PRJNA565445 | ENA

Development of gene expression signatures for psoriasis

Project description:Development of gene expression signatures for psoriasis

| PRJNA751566 | ENA

Effect of Lenalidomide on human macrophages.

Project description:Lenalidomide, an IMiD® immunomodulatory agent used for the treatment of multiple myeloma (MM),is believed to target the stromal support, but its precise mechanism on the phenotype or the effector functions of macrophages is still unclear. To investigate the effect of lenalidomide on macrophages, M-CSF generated macrophages were treated with Lenalidomide and analyzed by RNA-seq.

2021-01-23 | GSE165332 | GEO

Development of gene expression signatures for HCV infection

Project description:Development of gene expression signatures for HCV infection

| PRJNA976636 | ENA

Development of gene expression signatures for liver cirrhosis

Project description:Development of gene expression signatures for liver cirrhosis

| PRJNA510345 | ENA